Randomised controlled trial of Advanced Hybrid Closed Loop in an Adult Population with Type 1 Diabetes (ADAPT): study protocol and rationale

Simona de Portu, Linda Vorrink, Roseline Re, John Shin, Javier Castaneda, Aklilu Habteab, Ohad Cohen, Simona de Portu, Linda Vorrink, Roseline Re, John Shin, Javier Castaneda, Aklilu Habteab, Ohad Cohen

Abstract

Introduction: For many people with type 1 diabetes who struggle to achieve glycaemic control with multiple daily injections of insulin (MDI) plus self-monitoring of blood glucose, MDI plus intermittently scanned continuous glucose monitoring (IS-CGM) or real-time continuous glucose monitoring (RT-CGM), or insulin administration using insulin pump therapy represent optimised care in many regions. Through technological advances an advanced hybrid closed loop (AHCL) system has been developed; studies of incremental effects relative to MDI plus IS-CGM are lacking.

Methods and analysis: The Advanced Hybrid Closed Loop study in Adult Population with Type 1 Diabetes (ADAPT) study is a multinational, prospective, open-label, confirmatory and exploratory randomised controlled trial to examine outcomes with the MiniMed 670G version 4.0 AHCL system (with an equivalent algorithm and commercialised as the MiniMed 780G system, referred to as AHCL) relative to MDI plus IS-CGM in adults with baseline HbA1c≥8.0%. An exploratory cohort will compare AHCL with MDI plus RT-CGM. The study will be conducted in approximately 124 adults on MDI plus either IS-CGM or RT-CGM for at least 3 months prior to screening. The primary endpoint will be the difference in mean HbA1c change from baseline to 6 months between the AHCL and the MDI plus IS-CGM arms. Secondary endpoints will include proportion of time spent in hypoglycaemic, euglycaemic and hyperglycaemic ranges.

Ethics and dissemination: The ADAPT study will be conducted in accordance with the requirements of the Declaration of Helsinki and local laws and regulations, and has been approved by ethics committees. The trial will provide valuable information on the incremental benefits that may be provided by AHCL for patients failing to achieve glycaemic targets on MDI plus IS-CGM or RT-CGM and form a basis for health economic evaluations to support market access.

Trial registration number: NCT04235504; Pre-results.

Keywords: diabetes & endocrinology; general diabetes.

Conflict of interest statement

Competing interests: SdP, LV, RR, JS, AH, JC and OC are employees of Medtronic.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study design. AHCL, advanced hybrid closed loop; IS-CGM, intermittently scanned continuous glucose monitoring; MDI, multiple daily injections; RT-CGM, real-time continuous glucose monitoring.

References

    1. Brown SA, Kovatchev BP, Raghinaru D, et al. . Six-Month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 2019;381:1707–17. 10.1056/NEJMoa1907863
    1. Leelarathna L, Choudhary P, Wilmot EG, et al. . Hybrid closed-loop therapy: where are we in 2021? Diabetes Obes Metab 2021;23:655–60. 10.1111/dom.14273
    1. Collyns OJ, Meier RA, Betts ZL, et al. . Improved glycemic outcomes with medtronic MiniMed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose Suspend in people with type 1 diabetes. Diabetes Care 2021;44:dc202250. 10.2337/dc20-2250
    1. McAuley SA, Lee MH, Paldus B, et al. . Six months of hybrid closed-loop versus manual insulin delivery with Fingerprick blood glucose monitoring in adults with type 1 diabetes: a randomized, controlled trial. Diabetes Care 2020;43:3024–33. 10.2337/dc20-1447
    1. Huo L, Harding JL, Peeters A, et al. . Life expectancy of type 1 diabetic patients during 1997-2010: a national Australian registry-based cohort study. Diabetologia 2016;59:1177–85. 10.1007/s00125-015-3857-4
    1. Petrie D, Lung TWC, Rawshani A, et al. . Recent trends in life expectancy for people with type 1 diabetes in Sweden. Diabetologia 2016;59:1167–76. 10.1007/s00125-016-3914-7
    1. Bjornstad P, Donaghue KC, Maahs DM. Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment? Lancet Diabetes Endocrinol 2018;6:809–20. 10.1016/S2213-8587(18)30035-4
    1. Foster NC, Beck RW, Miller KM, et al. . State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther 2019;21:66–72. 10.1089/dia.2018.0384
    1. NHS England . Flash glucose monitoring: national arrangements for funding of relevant diabetes patients, 2019. Available: [Accessed 11 Aug 2020].
    1. Grunberger G, Handelsman Y, Bloomgarden ZT, et al. . American association of clinical endocrinologists and American College of endocrinology 2018 position statement on integration of insulin pumps and continuous glucose monitoring in patients with diabetes mellitus. Endocr Pract 2018;24:302–8. 10.4158/PS-2017-0155
    1. American Diabetes Association . 7. Diabetes Technology: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S71–80. 10.2337/dc19-S007
    1. Jangam S, Dunn T, Xu Y, et al. . Flash glucose monitoring improves glycemia in higher risk patients: a longitudinal, observational study under real-life settings. BMJ Open Diabetes Res Care 2019;7:e000611. 10.1136/bmjdrc-2018-000611
    1. Landau Z, Abiri S, Gruber N, et al. . Use of flash glucose-sensing technology (FreeStyle Libre) in youth with type 1 diabetes: Awesome Study Group real-life observational experience. Acta Diabetol 2018;55:1303–10. 10.1007/s00592-018-1218-8
    1. van den Boom L, Karges B, Auzanneau M, et al. . Temporal trends and contemporary use of insulin pump therapy and glucose monitoring among children, adolescents, and adults with type 1 diabetes between 1995 and 2017. Diabetes Care 2019;42:2050–6. 10.2337/dc19-0345
    1. Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group. Diabetes Care 1988;11:725–32. 10.2337/diacare.11.9.725
    1. Renard E, Vague V, et al. , Bringer pour le groupe Evadiac . Validation psychométrique d’une version française du questionnaire d’évaluation de la qualité de vie du diabétique élaboré par le DCCT Research Group (DQOL). Diabetes Metab 1999;25:22.
    1. Bradley . The diabetes treatment satisfaction questionnaire: DTSQ. In: Handbook of psychology and diabetes, 1994.
    1. Health psychology research. Available: [Accessed 14 Sep 2021].
    1. Cox DJ, Irvine A, Gonder-Frederick L, et al. . Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987;10)::617–21. Sep-Oct;. 10.2337/diacare.10.5.617
    1. Hermanides J, Nørgaard K, Bruttomesso D, et al. . Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med 2011;28:1158–67. 10.1111/j.1464-5491.2011.03256.x
    1. Li G, Shih WJ, Xie T, et al. . A sample size adjustment procedure for clinical trials based on conditional power. Biostatistics 2002;3:277–87. 10.1093/biostatistics/3.2.277
    1. Chen YHJ, DeMets DL, Lan KKG. Increasing the sample size when the unblinded interim result is promising. Stat Med 2004;23:1023–38. 10.1002/sim.1688
    1. Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat Med 2011;30:3267–84. 10.1002/sim.4102
    1. SPIRIT Statement Website . Available: [Accessed 29 Mar 2021].
    1. Borot S, Benhamou PY, Atlan C. SFD), Société française d’endocrinologie (SFE); Évaluation dans le diabète des implants actifs Group (EVADIAC). Practical implementation, education and interpretation guidelines for continuous glucose monitoring: A French position statement. Diabetes Metab 2018;44:61–72.
    1. American Diabetes Association . 6. Glycemic Targets: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S61–70. 10.2337/dc19-S006
    1. Graham C, Monitoring CG. And global reimbursement: an update. Diabetes Technol Ther 2017;19:S60–6.
    1. De Ridder F, den Brinker M, De Block C. The road from intermittently scanned continuous glucose monitoring to hybrid closed-loop systems. Part B: results from randomized controlled trials. Ther Adv Endocrinol Metab 2019;10:2042018819871903. 10.1177/2042018819871903
    1. Jendle J, Pöhlmann J, de Portu S, et al. . Cost-Effectiveness analysis of the MiniMed 670G hybrid closed-loop system versus continuous subcutaneous insulin infusion for treatment of type 1 diabetes. Diabetes Technol Ther 2019;21:110–8. 10.1089/dia.2018.0328
    1. Brunton S. Therapeutic inertia is a problem for all of US. Clin Diabetes 2019;37:105–6. 10.2337/cd19-0009
    1. Brož J, Janíčková Žďárská D, Urbanová J, et al. . Current level of glycemic control and clinical inertia in subjects using insulin for the treatment of type 1 and type 2 diabetes in the Czech Republic and the Slovak Republic: results of a multinational, multicenter, observational survey (DIAINFORM). Diabetes Ther 2018;9:1897–906. 10.1007/s13300-018-0485-2
    1. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group . Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study. JAMA 2003;290:2159–67. 10.1001/jama.290.16.2159

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit